SIBP A10
Alternative Names: SIBP-A10Latest Information Update: 10 Oct 2025
At a glance
- Originator Shanghai Institute of Biological Products
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Oct 2025 Preclinical trials in Solid tumours in China (Parenteral)
- 03 Oct 2025 Shanghai Institute of Biological Products plans a phase I trial for Solid tumor (Late-stage disease, Metastatic disease) in China (NCT07205198)